The probe is directed at all CAR-Ts currently on the US market, including those that target CD19, as well as BCMA, ... As part of post-CAR-T therapy safety and surveillance, ...

CAR T cell therapy is a promising approach to treatment that might have the potential to put lupus into remission for long periods for some patients. However, it is very early in the research process ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with remission rates reaching as high as 90%. This therapy modifies a patient ...

While CAR T cell therapy—a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn—has revolutionized treatment for many blood cancers ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

CAR-T cell therapy involves extracting a patient's T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.

Chimeric antigen receptor (CAR) T-cell therapy has been an exciting area of development for autoimmune disease treatment. Previous reports had not mentioned any particular constellation of adverse ...

A novel autologous CAR-T therapy, YTB323, with preserved t-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov 2023;13:1982-1997. Crossref ...

Chong EA, Ruella M, Schuster SJ. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. N Engl J Med. 2021;384(7):673–4. Raj SS, Fei T, Fried S, et al. An inflammatory biomarker ...

A CAR T cell therapy clinical trial is conducted by a multidisciplinary care team that oversees the preparation, administration, and follow up of the therapy. The clinical trial care team consists of ...